FDA Approves ACTHAR — Keenova ARD LLC

Keenova ARD LLC has announced FDA approval for Repository Corticotropin Injection (Acthar), a long-established therapy originally approved in 1952, expanding critical options for treating certain autoimmune disorders and severe infant spasms. This landmark approval ensures continued market availability of the biologic, providing a vital lifeline for patients historically reliant on this specific injectable product.